回顾性分析780例首次冠脉介入术后双联抗血小板发生出血事件的风险  

Analysis of the risk of hemorrhages for 780 cases of patients receiving dual antiplatelet therapy after first PCI

作　　者：周陶然[1] 钱石静[1] 沈筱云[1] 黄之训[1] 

机构地区：[1]上海市同济医院,上海200065

出　　处：《上海医药》2016年第1期52-54,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探讨首次经皮冠状动脉介入术(PCI)后联用阿司匹林、氯吡格雷患者1年内发生出血事件的风险及影响因素。方法:回顾调查2009年6月1日-2012年5月31日入院的病例(剔除可影响凝血的合并用药和基础疾病)。分析导致出血事件和严重出血事件(导致住院)的影响因素。结果:总共780例,其中出血43例,严重出血11例。出血组和无出血组比较,性别、年龄、高血压、糖尿病、高脂血症皆无差异。严重出血组和出血组比较,有糖尿病者分别占63.6%和26.3%,平均年龄分别为72.6岁和64.5岁,均有显著差异(P<0.05)。结论:对于总体出血事件,性别、年龄、高血压、糖尿病、高脂血症均无影响。对于严重出血事件,年龄、糖尿病可能是影响因素。Objective：To investigate the risk of hemorrhages for the patients who took both aspirin and clopidogrel after first percutaneous coronary intervention（PCI） in one year.Methods：Seven hundred and eighty cases of the patients hospitalized from June 1,2009 to May 31,2012 were retrospectively studied,in which the patients receiving combination therapy that can influence coagulation or with other diseases were excluded.The influencing factors resulting in hemorrhages and severe hemorrhages（ leading to hospitalization） were analyzed.Results：Hemorrhages and severe hemorrhages happened in 43 and 11 patients.There were no significant differences in gender,age,hypertension,diabetes,hyperlipidemia between hemorrhage group and non-hemorrhage group.The patients with diabetes accounted for 63.6% in severe-hemorrhage-group and 26.3% in non-severe-hemorrhage-group and the average age was 72.6 years in severe-hemorrhage-group and 64.5 years in non-severehemorrhage-group,which showed significant differences（P〈0.05）.Conclusion：The overall hemorrhage events would not be affected by gender,age,hypertension,diabetes,however,the severe hemorrhage events may be done by some influencing factors such as age and diabetes.

关 键 词：阿司匹林 氯吡格雷 出血事件 

分 类 号：R541.4[医药卫生—心血管疾病]